Haegarda Kit
Product Images NDC 63833-828

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Haegarda (NDC 63833-828). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Csl Behring Gmbh, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Haegarda 01)

HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) kit packaging label showing a white, round plastic container with a wide base and narrow neck, designed for the plasma derivative product by CSL Behring GmbH.*

FDA Label Image

Figure 2 (Haegarda 02)

An instructional diagram showing a vial and a syringe adapter. The image illustrates the connection of the syringe adapter onto the vial, likely part of preparation steps for HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) kit from CSL Behring GmbH.*

FDA Label Image

Figure 3 (Haegarda 03)

An instructional drawing showing a vial and a syringe with a plunger. The image illustrates a step in medication preparation, likely depicting the attachment or removal of the syringe from the vial.*

FDA Label Image

Figure 4 (Haegarda 04)

An instructional diagram showing the assembly of a vial and a cap with a syringe or needle attachment. The image illustrates the steps to prepare or access the contents of a vial, likely related to the HAEGARDA C1 Esterase Inhibitor Subcutaneous kit components.*

FDA Label Image

Figure 5 (Haegarda 05)

Packaging label image showing a vial of HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) in a kit format. The vial appears clear with a label wrapped around its midsection, topped with a capped closure. The product is a plasma derivative manufactured by CSL Behring GmbH.*

FDA Label Image

Figure 6 (Haegarda 06)

An instructional diagram illustrating the process of connecting two medical vials or containers. It shows twisting motion arrows indicating how to attach the two parts securely, likely for medication preparation or reconstitution.*

FDA Label Image

Figure 7 (Haegarda 07)

An instructional diagram illustrating a step in the preparation of a subcutaneous injection, showing a syringe with a plunger being pulled downward. This is likely part of the administration process for HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) kit by CSL Behring GmbH.*

FDA Label Image

Figure 8 (Haegarda 08)

An instructional illustration showing how to detach the plunger cap from a syringe by twisting it counterclockwise. The drawing depicts a syringe with a removable cap being unscrewed, intended to guide proper assembly or preparation usage steps.*

FDA Label Image

Figure 9 (Haegarda 09)

An illustration shows a cylindrical container with an open top featuring a cross-shaped support structure inside. This diagram likely represents a component related to the HAEGARDA C1 Esterase Inhibitor Subcutaneous kit by CSL Behring GmbH.*

FDA Label Image

Figure 10 (Haegarda 10)

An instructional diagram showing a vial with a bottle below it and a downward arrow indicating that the vial content or stopper should be pushed down into the bottle. This likely illustrates a step in reconstituting or mixing medication from a vial into a bottle.*

FDA Label Image

Figure 11 (Haegarda 11)

An instructional illustration showing components of a reconstitution kit for a medication. It depicts a vial with a stopper, a cap with an arrow indicating removal, and a syringe or connector, suggesting steps for preparing a drug from a vial using the kit.*

FDA Label Image

Figure 12 (Haegarda 12)

A black and white instructional diagram showing the assembly or connection of two vial components, likely for use with the HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) kit. The illustration indicates how to align and attach the parts, with an arrow pointing to the connection area.*

FDA Label Image

Principal Display Panel (Kit Carton)

An instructional or technical line drawing illustration showing a vial attached to a syringe or applicator device. The image likely represents the components or assembly for administering HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) in a kit form by CSL Behring GmbH.*

FDA Label Image

Principal Display Panel (Kit Carton)

An instructional illustration showing the process of assembling or connecting two vial components by aligning and twisting them together. The image features two containers, one placed above the other, with a curved arrow indicating the direction of the twist to secure the connection.*

FDA Label Image

Haegarda 15

An instructional illustration showing a syringe with a plunger being pushed downward, indicating the action of injecting or dispensing the liquid from the syringe. No text or specific product branding is visible.*

FDA Label Image

Haegarda 16

An instructional illustration showing the assembly of a syringe and vial. The image depicts a vial being aligned with a syringe, demonstrating how to connect the two parts for medication preparation.*

FDA Label Image

Haegarda 17

An instructional diagram showing a male torso with marked subcutaneous injection sites on the abdomen and lower chest area. The image is associated with HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) KIT by CSL Behring GmbH, illustrating recommended injection locations for this plasma derivative medication.*

FDA Label Image

Haegarda 18

Illustration showing a hand holding a cleansing wipe, preparing to clean a skin area, likely as part of a subcutaneous injection procedure for HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) kit by CSL Behring GmbH.*

FDA Label Image

Haegarda 19

An instructional line drawing showing a person using a syringe to withdraw medication from a vial by inserting the needle through the vial's rubber stopper and pulling back the plunger to draw up the liquid. This illustration likely demonstrates part of the preparation process for administering HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) Kit.*

FDA Label Image

Haegarda 20

An instructional line drawing showing a person adjusting or preparing a device or catheter on their forearm, indicating a step in the use of a medical kit, possibly for subcutaneous injection.*

FDA Label Image

Haegarda 21

Packaging label for HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) 2000 IU kit, containing one single-dose vial and sterile water for injection. The label shows the proprietary and generic names, dosage form, and indicates subcutaneous administration only. Manufactured by CSL Behring GmbH, Germany, and distributed by CSL Behring LLC, USA.*

FDA Label Image

Haegarda 22

Packaging label for HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) kit, 3000 IU. The label indicates the product is for subcutaneous administration only and includes one single-dose vial and sterile water for injection. Manufactured by CSL Behring GmbH, Germany, and distributed by CSL Behring LLC, USA. Storage instructions note stability up to 30°C and protection from light.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.